drugset
drugset / Trial / NCT04098692

Mass Balance and Pharmacokinetics Study of Derazantinib in Healthy Male Subjects

NCT04098692 ↗

Phase 1 Completed 12 enrolled Basilea Pharmaceutica
NaSingle-groupOpen-labelOther

Summary

This is a Phase 1, two-part, open-label, single centre, single arm study in healthy male subjects to investigate the oral PK, intravenous (IV) PK, mass balance, bioavailability and metabolites profiling and identification of derazantinib.

Timeline

Start
2019-08-08
Primary completion
2019-11-18
Completion
2019-11-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Derazantinib Small molecule 100 ug Oral
Subject Derazantinib Small molecule 300 mg Oral

Indications

No indication recorded.